Effects of the CYP 2D6 Genotype and Cigarette Smoking on the Steady-State Plasma Concentrations of Fluvoxamine and Its Major Metabolite Fluvoxamino Acid in Japanese Depressed Patients-Reference-Cited by-同舟云学术

Effects of the CYP 2D6 Genotype and Cigarette Smoking on the Steady-State Plasma Concentrations of Fluvoxamine and Its Major Metabolite Fluvoxamino Acid in Japanese Depressed Patients

Published:2003-08 Issue:4 Volume:25 Page:463-468
ISSN:0163-4356
Container-title:Therapeutic Drug Monitoring
language:en
Short-container-title:Therapeutic Drug Monitoring

Author:

Gerstenberg Gisa,Aoshima Toshiaki,Fukasawa Takashi,Yoshida Keizo,Takahashi Hitoshi,Higuchi Hisashi,Murata Yoshiko,Shimoyama Ritsuko,Ohkubo Tadashi,Shimizu Tetsuo,Otani Koichi

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Pharmacology

Reference41 articles.

1. Fluvoxamine

2. Fluvoxamine maleate: metabolism in man

3. Review of the animal pharmacology and pharmacokinetics of fluvoxamine.

4. Polymorphic Drug Oxidation

5. Pharmacogenetics of Classical and New Antipsychotic Drugs

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Serum Concentration–Dose Relationship and Modulation Factors in Children and Adolescents Treated with Fluvoxamine;Pharmaceutics;2024-06-06

2. Metabolomic Investigation of Major Depressive Disorder Identifies a Potentially Causal Association With Polyunsaturated Fatty Acids;Biological Psychiatry;2023-10

3. Association of CYP2C19 and CYP2D6 Poor and Intermediate Metabolizer Status With Antidepressant and Antipsychotic Exposure;JAMA Psychiatry;2021-03-01

4. Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder;Pharmacogenomics and Personalized Medicine;2018-06

5. Smoking and antidepressants pharmacokinetics: a systematic review;Annals of General Psychiatry;2017-03-06